Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...

Patricia Clarkson plays the equal pay activist Lilly Ledbetter in this misty-eyed drama.

Patricia Clarkson on "Lilly," and the fight of fair pay activist Lilly Ledbetter If you don't know the name Lilly Ledbetter, how's this for an introduction? "Lilly Ledbetter did not set out to be ...

Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.